Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EW
stocks logo

EW

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.54B
+11.11%
0.617
+4.56%
1.57B
+11.07%
0.680
+6.19%
1.67B
+9.09%
0.724
+8%
Estimates Revision
The market is revising Upward the revenue expectations for Edwards Lifesciences Corporation (EW) for FY2025, with the revenue forecasts being adjusted by 1.02% over the past three months. During the same period, the stock price has changed by 5.98%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.02%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.32%
In Past 3 Month
Stock Price
Go Up
up Image
+5.98%
In Past 3 Month
Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 92.95 USD with a low forecast of 83.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 92.95 USD with a low forecast of 83.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
10 Hold
0 Sell
Moderate Buy
Current: 85.780
sliders
Low
83.00
Averages
92.95
High
104.00
Current: 85.780
sliders
Low
83.00
Averages
92.95
High
104.00
UBS
Neutral
maintain
$85 -> $90
2025-11-03
Reason
UBS
Price Target
$85 -> $90
2025-11-03
maintain
Neutral
Reason
UBS raised the firm's price target on Edwards Lifesciences to $90 from $85 and keeps a Neutral rating on the shares. Edwards Lifesciences posted a broad-based beat and raise quarter and raised the full year TAVR guidance to 7%-8%, which UBS views as conservative, the analyst tells investors in a research note. UBS remains on the sidelines for now as it's still unclear whether the sustainable mid-term TAVR growth trajectory is better than mid-to-high single digits.
Goldman Sachs
Buy
maintain
$94 -> $104
2025-11-03
Reason
Goldman Sachs
Price Target
$94 -> $104
2025-11-03
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Edwards Lifesciences to $104 from $94 and keeps a Buy rating on the shares.
Truist
Hold
maintain
$87 -> $90
2025-11-03
Reason
Truist
Price Target
$87 -> $90
2025-11-03
maintain
Hold
Reason
Truist raised the firm's price target on Edwards Lifesciences to $90 from $87 and keeps a Hold rating on the shares. The company delivered a solid Q3 revenue and earnings beat, marked by a return to 10% constant currency TAVR growth and a 2% TMTT beat while reflecting accelerating revenue growth, the analyst tells investors in a research note.
Raymond James
Jayson Bedford
Market Perform
to
Outperform
upgrade
$96
2025-11-03
Reason
Raymond James
Jayson Bedford
Price Target
$96
2025-11-03
upgrade
Market Perform
to
Outperform
Reason
Raymond James analyst Jayson Bedford upgraded Edwards Lifesciences to Outperform from Market Perform with a $96 price target. The company has "various opportunities" for better growth, which should drive multiple expansion for the shares, the analyst tells investors in a research note. The firm says Edwards' transcatheter aortic valve replacement growth is improving, bolstered by the potential of asymptomatic adoption, while the company's transcatheter mitral and tricuspid therapies business is "better positioned today than even before."
Canaccord
Hold
maintain
$81 -> $84
2025-11-03
Reason
Canaccord
Price Target
$81 -> $84
2025-11-03
maintain
Hold
Reason
Canaccord raised the firm's price target on Edwards Lifesciences to $84 from $81 and keeps a Hold rating on the shares. The firm said its Q3 results were led by TAVR as the company benefited from increased awareness of aortic stenosis, driven by the stream of clinical data and podium presentations from its asymptomatic work; but likely still isn't treating asymptomatic patients, due to coverage limitations.
RBC Capital
Outperform
maintain
$89 -> $95
2025-10-31
Reason
RBC Capital
Price Target
$89 -> $95
2025-10-31
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Edwards Lifesciences to $95 from $89 and keeps an Outperform rating on the shares. The company delivered a Q3 sales and earnings upside surprise of 4%/12%, driven by TAVR outperformance and TMTT/surgery beats, the analyst tells investors in a research note. Sentiment on Edwards Lifesciences has shifted positively of late post TCT updates and Q3 print as several of its catalysts take hold for a multi-year runway, RBC added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Edwards Lifesciences Corp (EW.N) is 30.61, compared to its 5-year average forward P/E of 34.82. For a more detailed relative valuation and DCF analysis to assess Edwards Lifesciences Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
34.82
Current PE
30.61
Overvalued PE
41.77
Undervalued PE
27.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
27.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
32.95
Undervalued EV/EBITDA
21.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
9.16
Current PS
0.00
Overvalued PS
11.29
Undervalued PS
7.02
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased368.75%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

EW News & Events

Events Timeline

(ET)
2025-12-04
09:20:00
Edwards Sees FY26 Revenue of $6.4B-$6.8B
select
2025-12-04
09:10:00
Edwards Lifesciences Raises FY25 Revenue Outlook to 9%-10%
select
2025-10-30 (ET)
2025-10-30
16:21:07
Edwards Lifesciences CFO Ullem to Step Down by Mid-2026
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-01PRnewswire
Halper Sadeh Investigates Edwards Lifesciences for Potential Fiduciary Breaches
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers of Edwards Lifesciences breached their fiduciary duties, which could impact corporate governance and shareholder rights.
  • Legal Relief Options: Long-term shareholders of Edwards may seek corporate governance reforms, fund recovery, or court-approved financial incentives, aimed at enhancing transparency and accountability within the company.
  • Importance of Participation: Shareholder involvement can improve company policies and oversight mechanisms, thereby enhancing shareholder value and promoting more effective management practices.
  • Legal Fee Arrangement: The law firm will handle the case on a contingent fee basis, meaning shareholders will not incur upfront legal costs, thus reducing the financial burden of participating in the rights enforcement process.
[object Object]
Preview
9.5
11-28NASDAQ.COM
Edwards Lifesciences (EW) Earnings Call Transcript
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
8.5
11-27WSJ
Corporate Mergers and Acquisitions Are Expanding and Intensifying During Trump's Presidency

  • Corporate Mergers on the Rise: There is an increase in corporate mergers, particularly among direct competitors, as companies are more willing to pursue these deals.

  • Impact of Trump Administration: The Trump administration's relaxed enforcement policies are contributing to this surge in corporate tie-ups, according to bankers and lawyers.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Edwards Lifesciences Corp (EW) stock price today?

The current price of EW is 85.78 USD — it has increased 2.14 % in the last trading day.

arrow icon

What is Edwards Lifesciences Corp (EW)'s business?

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

arrow icon

What is the price predicton of EW Stock?

Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 92.95 USD with a low forecast of 83.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Edwards Lifesciences Corp (EW)'s revenue for the last quarter?

Edwards Lifesciences Corp revenue for the last quarter amounts to 1.55B USD, increased 14.67 % YoY.

arrow icon

What is Edwards Lifesciences Corp (EW)'s earnings per share (EPS) for the last quarter?

Edwards Lifesciences Corp. EPS for the last quarter amounts to 0.50 USD, decreased -90.25 % YoY.

arrow icon

What changes have occurred in the market's expectations for Edwards Lifesciences Corp (EW)'s fundamentals?

The market is revising Upward the revenue expectations for Edwards Lifesciences Corporation (EW) for FY2025, with the revenue forecasts being adjusted by 1.02% over the past three months. During the same period, the stock price has changed by 5.98%.
arrow icon

How many employees does Edwards Lifesciences Corp (EW). have?

Edwards Lifesciences Corp (EW) has 15800 emplpoyees as of December 05 2025.

arrow icon

What is Edwards Lifesciences Corp (EW) market cap?

Today EW has the market capitalization of 49.78B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free